THLD to Outperform its 52-High

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) experienced the highest weekly growth following the deal with Merck KGaA estimated at approximately up to $550 million.

After trading for more than six months at the level well below $2.00 THLD surged $1.70 or 131.78%. As a result of the most unusual trading moving up the company ended up at $2.99 before the closing bell. Furthermore, in the course of trading the company set up its new 52-high of $3.01. At the current price the company’s market capitalization stands at $146.81 million, which means that THLD is referred to a group of small cap companies.

Following the stock selling and buying trading signals as many as 13.17 million shares of the company exchanged hands, while its average trading volume calculated on a 30-day basis amounts to 614,891.00. The company owns 49.13 million outstanding shares that are engaged in stock market portfolios of multiple investors.

The unusual change in the share price resulted from the recently signed deal with Merck KGaA aimed at developing and commercialization of the Threshold's cancer candidate, TH-302.

According to the terms and conditions of the deal the companies agreed to cooperate on the cancer treatment development. Moreover, Merck is to provide about 70% of financing the product development. After receiving the approval from Food and Drug Administration (FDA) Merck will also contribute to the marketing and commercialization of the product. THLD in its turn reserves the right to participate in co-promotion, getting royalties on sales and receiving profits in the USA.

Threshold Pharmaceuticals, Inc. is engaged in the Biotechnology and Drugs industry of the Healthcare sector. The company operated in the area of research and development of medicines aimed at treating cancer.